Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health todayExpanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today

Mira Precision Health, Based in Mason, Ohio, Announces U.S. Launch of ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium

Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine

MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today announced the official U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA®).

This launch comes amid heightened concern regarding fluoropyrimidine safety in certain patient populations. The U.S. Food and Drug Administration recently updated the XELODA® (capecitabine) prescribing information to include a Black Box Warning highlighting the risk of severe, life-threatening, and potentially fatal toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This warning underscores the urgent need for proactive identification of genetically at-risk patients prior to initiating treatment with fluoropyrimidines.

Key features of ToxNav® Advantage™ include:

  • Comprehensive analysis of 23 DPYD gene variants
  • Inclusion of DGLUCY and ENOSF1/TYMS variants predictive of fluoropyrimidine-associated cardiotoxicity (CTRCD) and Hand-Foot Syndrome (HFS)
  • Rapid 48-hour turnaround time for clinically actionable results
  • Clear, clinician-friendly reports that support dose optimization, reduced hospitalizations, and lower treatment-related mortality

The launch will be highlighted by a Mira-sponsored Industry Expert Theater (IET) session at the 2026 ASCO® Gastrointestinal Cancers Symposium in San Francisco, CA.

The 45-minute session, titled “From Oxford to the U.S.: The Clinical Utility Evolution of ToxNav® Advantage™ in Preventing 5-FU/Capecitabine Toxicities,” will be presented by Abdul Rahman Jazieh, MD, MPH, Chief Medical Officer of Mira Precision Health. Dr. Jazieh will discuss a real-world case study of fluoropyrimidine-induced cardiovascular toxicity demonstrating the clinical value of variant testing in identifying at-risk patients and informing care decisions.

Professor David Kerr, CBE, MA, MSc, MD, PhD, DSc, FRCP, founder of the original ToxNav® program, internationally recognized oncology researcher, and Chair of Mira Precision Health’s Scientific Advisory Board, will also be onsite throughout ASCO-GI. As the architect of ToxNav’s scientific foundation and a global leader in fluoropyrimidine toxicity research, Professor Kerr will support the U.S. debut of ToxNav® Advantage™ and be available for expert discussions with clinicians, researchers, and industry stakeholders.

ToxNav® Advantage™ builds on more than a decade of peer-reviewed clinical research and real-world implementation of ToxNav® across U.K. and E.U. healthcare systems. The test analyzes 26 clinically relevant gene variants, including 23 DPYD variants aligned with the Association for Molecular Pathology (AMP) 2025 Tier 1 and Tier 2 classifications, along with additional Oxford-validated markers. ToxNav® Advantage™ uniquely extends fluoropyrimidine toxicity risk assessment beyond DPYD deficiency by incorporating genetic variants associated with cancer therapy–related cardiac dysfunction (CTRCD)—a potentially life-threatening complication—and Hand-Foot Syndrome (HFS), a frequent cause of treatment modification or discontinuation in patients receiving fluoropyrimidines.

“We developed ToxNav® to identify patients with a high likelihood of severe toxicity from 5-FU and capecitabine—two of the most widely prescribed cancer therapies worldwide,” said Professor Kerr. “Through our collaboration with Mira Precision Health, ToxNav® has been optimized for the U.S. market, delivering greater clinical utility and rapid turnaround times that can meaningfully improve patient outcomes.”

“ToxNav® Advantage™ provides oncologists with fast, actionable insights to help prevent life-threatening toxicities before treatment begins,” said Dr. Jazieh. “Our mission is to enable precision-driven care that protects patients across every stage of therapy.”

“As a long-time partner of Mira and strong advocate for life science advancement, we’re excited to see this partnership with Oxford bring life-changing technology to the U.S.,” said Michele Blair, Director of Economic Development for the City of Mason. “We’re leaning in to our ‘Mason Living Lab’ platform, which engages city residents and employees as participants to advance new technology. This program differentiates Mason’s position in the Midwestern ecosystem and accelerates science discovery.”

About Mira Precision Health

Mira Precision Health is a CLIA-certified, high-complexity clinical laboratory headquartered in Mason, Ohio, specializing in precision medicine diagnostics. Through its advanced pharmacogenomic and oncology testing solutions, Mira empowers clinicians nationwide to deliver safer, more personalized cancer care.

About the City of Mason, Ohio

The City of Mason, Ohio, is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. Mason was one of the first cities in Ohio designated a Premier Life Science Ready Community in 2025 by the Ohio Life Sciences Association for its infrastructure readiness, dedicated support systems, accessible real estate and high-quality resources that make it attractive to life science development. For more information about the City of Mason, visit www.whymason.com or www.imaginemason.org.

For media inquiries, please contact:
Lori Borchers
Vice President, Sales and Marketing
Mira Precision Health
Email: [email protected]
Website: https://www.miraprecision.com/toxnav/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mira-precision-health-based-in-mason-ohio-announces-us-launch-of-toxnav-advantage-at-the-2026-asco-gi-cancers-symposium-302652722.html

SOURCE City of Mason

Market Opportunity
Mira Logo
Mira Price(MIRA)
$0.1235
$0.1235$0.1235
+0.16%
USD
Mira (MIRA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future

UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future

The post UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future appeared on BitcoinEthereumNews.com. Key Highlights Microsoft and Google pledge billions as part of UK US tech partnership Nvidia to deploy 120,000 GPUs with British firm Nscale in Project Stargate Deal positions UK as an innovation hub rivaling global tech powers UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future The UK and the US have signed a “Technological Prosperity Agreement” that paves the way for joint projects in artificial intelligence, quantum computing, and nuclear energy, according to Reuters. Donald Trump and King Charles review the guard of honour at Windsor Castle, 17 September 2025. Image: Kirsty Wigglesworth/Reuters The agreement was unveiled ahead of U.S. President Donald Trump’s second state visit to the UK, marking a historic moment in transatlantic technology cooperation. Billions Flow Into the UK Tech Sector As part of the deal, major American corporations pledged to invest $42 billion in the UK. Microsoft leads with a $30 billion investment to expand cloud and AI infrastructure, including the construction of a new supercomputer in Loughton. Nvidia will deploy 120,000 GPUs, including up to 60,000 Grace Blackwell Ultra chips—in partnership with the British company Nscale as part of Project Stargate. Google is contributing $6.8 billion to build a data center in Waltham Cross and expand DeepMind research. Other companies are joining as well. CoreWeave announced a $3.4 billion investment in data centers, while Salesforce, Scale AI, BlackRock, Oracle, and AWS confirmed additional investments ranging from hundreds of millions to several billion dollars. UK Positions Itself as a Global Innovation Hub British Prime Minister Keir Starmer said the deal could impact millions of lives across the Atlantic. He stressed that the UK aims to position itself as an investment hub with lighter regulations than the European Union. Nvidia spokesman David Hogan noted the significance of the agreement, saying it would…
Share
BitcoinEthereumNews2025/09/18 02:22
Ondo Finance launches USDY yieldcoin on Stellar network

Ondo Finance launches USDY yieldcoin on Stellar network

The post Ondo Finance launches USDY yieldcoin on Stellar network appeared on BitcoinEthereumNews.com. Key Takeaways Ondo Finance has launched its USDY yieldcoin on the Stellar blockchain network. USDY is Ondo’s flagship yieldcoin focused on real-world asset expansion. Ondo Finance launched its USDY yieldcoin on the Stellar blockchain network today. USDY is described as Ondo’s flagship yieldcoin and represents the company’s expansion of real-world assets onto the Stellar platform. The launch aims to provide yield access across global economies through Stellar’s international network infrastructure. The deployment connects traditional finance with blockchain-based solutions by bringing real-world asset exposure to Stellar’s ecosystem. Ondo Finance positions the move as part of efforts to broaden access to yield-generating opportunities worldwide. Source: https://cryptobriefing.com/ondo-finance-usdy-yieldcoin-stellar-launch/
Share
BitcoinEthereumNews2025/09/18 03:58
ZK-powered Bitcoin Layer 2 Citrea launches mainnet

ZK-powered Bitcoin Layer 2 Citrea launches mainnet

Citrea uses a zero-knowledge Ethereum Virtual Machine to inscribe its chain history on the Bitcoin base layer.
Share
Coinstats2026/01/27 22:01